Clinical trials
Breast Cancer Invasive clinical trials
Below are recruiting breast cancer invasive clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07380646RecruitingPhase 2
Leucogen to prevent low white blood cells from ribociclib in early breast cancer
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hangzhou, ZhejiangAges 18 years+ - NCT07335354Recruiting
Decision tool for breast reconstruction after mastectomy
This study is testing a decision tool to help people who are thinking about breast reconstruction surgery after a mastectomy. The tool is designed to help you and your doctor make a more informed choice.
Basking Ridge, New JerseyAges 18 years+ - NCT05693766RecruitingPhase 2
Gene test guides treatment for hormone-positive breast cancer
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
Birmingham, AlabamaAges 18 years+ - NCT04437160RecruitingPhase 2
Chemo after surgery for triple-negative breast cancer with leftover tumor
This Phase 2 study tests chemotherapy given after surgery for people with triple-negative breast cancer who still have cancer left after initial (neoadjuvant) chemo. It may help lower the chance the cancer comes back in people at higher risk based on leftover tumor and lymph node findings.
Beijing, Beijing MunicipalityAges 18–75 - NCT07739485RecruitingPhase 1/Phase 2
Oral paclitaxel before surgery for triple-negative breast cancer
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
Guiyang, GuizhouAges 18–70 - NCT07672392Recruiting
Exercise after breast reconstruction surgery
This trial tests whether a structured exercise program after DIEP flap breast reconstruction helps improve physical fitness compared to standard care. It may help women recover strength and well-being after surgery.
Beaumont, DublinAges 18 years+ - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06176534RecruitingPhase 2
Comparing two treatments for advanced breast cancer with low hormone receptor
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
Zhengzhou, HenanAges 18 years+ - NCT06341621RecruitingPhase 3
Skipping chemo for ER+/HER2- breast cancer with 1–3 positive nodes
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
ShanghaiAges 18–80 - NCT07263451Recruiting
Testing a new treatment for small, early breast cancers
This study tests if a new treatment called IRE (irreversible electroporation) can safely treat small, early-stage breast cancers. It's for people with a single, small tumor that has not been treated yet.
Hangzhou, ZhejiangAges 18 years+ - NCT07137871RecruitingPhase 1
Avasopasem for advanced HR+ breast cancer after CDK 4/6 inhibitor
This trial tests a drug called avasopasem for people with hormone receptor-positive, HER2-negative breast cancer that has spread and gotten worse despite treatment with a CDK 4/6 inhibitor (ribociclib or abemaciclib) and hormonal therapy. It aims to see if adding avasopasem can help control the cancer.
San Antonio, TexasAges 18 years+ - NCT05360290Recruiting
Study checks cancer cells in breast tissue after surgery
This trial looks for circulating tumor cells—cancer cells that may travel in the blood—after standard breast cancer treatment, including chemotherapy before surgery and surgery itself. It may help doctors understand who might be at higher risk and tailor follow-up care.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07743190RecruitingPhase 2
Lighter chemo for early-stage triple-negative breast cancer with high immune cells
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
Syracuse, New YorkAges 18 years+ - NCT04817540RecruitingPhase 2
Testing anti-HER2 treatment for HER2-enriched early breast cancer
This trial tests an anti-HER2 medicine in people whose breast cancer is classified as “HER2-enriched” using a special lab test (PAM50). It aims to see whether this treatment can help prevent or control cancer that cannot be fully removed by surgery.
SeoulAges 19 years+ - NCT07629206Recruiting
Freezing therapy for small, early-stage breast cancer
This study tests whether freezing a small breast tumor (cryoablation) is a safe and effective treatment option for older adults with early-stage, hormone-receptor-positive breast cancer. Instead of surgery, the goal is to destroy the tumor by freezing it in place.
Glendale, CaliforniaAges 70 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT07010939Recruiting
Side effects and quality of life after breast cancer treatment in China
This study looks at how local treatments like surgery, chemotherapy, radiation, hormone therapy, or targeted therapy affect your side effects and quality of life. Researchers want to learn from women with early-stage breast cancer to improve care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07372079RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for early triple-negative breast cancer
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
TianjinAges 18–75 - NCT05911958RecruitingPhase 2
Study drug before surgery for HER2-low, HR-positive breast cancer
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
Zhengzhou, HenanAges 18–70 - NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06878625RecruitingPhase 2
Trop-2 drug combo for advanced triple-negative breast cancer
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT05939830Recruiting
Skipping axillary lymph node surgery after treatment response
This study looks at whether some breast cancer patients can safely skip a surgery that removes lymph nodes in the armpit after their initial (pre-surgery) treatment shows the armpit is likely clear. It may reduce surgical side effects if the armpit truly responds well.
NanjingAges 18–70 - NCT03265379Recruiting
Registry study for breast cancer invading the chest wall
This study follows people with breast cancer that has spread into the chest wall who are planning full-thickness chest wall surgery. It aims to improve quality of life by collecting real-world information during and after treatment.
Toronto, OntarioAges 18 years+
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer invasive?
- Yes. Clin2 currently lists 717 recruiting breast cancer invasive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer invasive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer invasive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.